Orphan designation: Dersimelagon Treatment of erythropoietic protoporphyria, 16/03/2022 Positive
Retrieved on:
Monday, December 18, 2023
Medicine, COMP, Prevalence, Update, European Commission, Trick or Treatment?, Mitsubishi Tanabe Pharma, Phototoxicity, EPP, Disease, Narcolepsy, EMA, Civil service commission, Patient, Agency, European, MC1R, Marketing, Committee, Pigment, Community, Diagnosis, Pain, No Date, No Signature, Erythropoietic protoporphyria, Skin, EURORDIS, Heerdt, Pharmaceutical industry, Medical device, Fine chemical
Overview
Key Points:
- Overview
This medicine was designated as an orphan medicine for the treatment of erythropoietic protoporphyria in the European Union on 16 March 2022. - All medicines, including designated orphan medicines, must be authorised before they can be marketed and made available to patients in the EU.
- The full list of orphan designations is available in the Community register of orphan medicinal products for human use.
- EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: